Ray Dalio’s Veracyte VCYT Stock Holding History

Ray Dalio’s Portfolio VCYT Stock Details VCYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.95M	Buy	91,590 +63,196	+223%	+$2.34M	0.01%	561
2025 Q4	$1.2M	Buy	+28,394	New	+$1.14M	﹤0.01%	855

Other funds holding VCYT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Ray Dalio's VCYT Position: Q1 2026 in Review

Ray Dalio increased its Veracyte (VCYT) stake by 223% in Q1 2026, buying an estimated $2.34M and bringing the position to 91,590 shares worth $2.95M. The position accounts for 0.01% of the portfolio, ranked #561.

Ray Dalio first reported a position in VCYT in Q4 2025 and has held it in 2 quarters since. 334 funds tracked by Wall St. Rank hold VCYT as of Q1 2026.

Ray Dalio held 91,590 shares of Veracyte worth $2.95M as of Q1 2026.
Ray Dalio bought 63,196 Veracyte shares in Q1 2026, an estimated $2.34M.
Veracyte made up 0.01% of Ray Dalio's portfolio in Q1 2026, its #561 holding.
Ray Dalio first reported a position in Veracyte in Q4 2025 and has held it in 2 quarters since.
334 funds tracked by Wall St. Rank held Veracyte as of Q1 2026.

Based on Bridgewater Associates's 13F filing for Q1 2026, filed 15 May 2026.